These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 7506122)
1. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Guo YJ; Liu G; Wang X; Jin D; Wu M; Ma J; Sy MS Cancer Res; 1994 Jan; 54(2):422-6. PubMed ID: 7506122 [TBL] [Abstract][Full Text] [Related]
2. Soluble CD44: quantification and molecular repartition in plasma of patients with colorectal cancer. Masson D; Denis MG; Denis M; Blanchard D; Loirat MJ; Cassagnau E; Lustenberger P Br J Cancer; 1999 Aug; 80(12):1995-2000. PubMed ID: 10471052 [TBL] [Abstract][Full Text] [Related]
3. Serum HDL-C as a potential biomarker for nodal stages in gastric cancer. Guo E; Chen L; Xie Q; Chen J; Tang Z; Wu Y Ann Surg Oncol; 2007 Sep; 14(9):2528-34. PubMed ID: 17597347 [TBL] [Abstract][Full Text] [Related]
4. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117 [TBL] [Abstract][Full Text] [Related]
5. Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N Cancer; 1998 Sep; 83(6):1094-101. PubMed ID: 9740073 [TBL] [Abstract][Full Text] [Related]
6. Soluble CD44 standard, CD44 variant 5 and CD44 variant 6 and their relation to staging in head and neck cancer. Kawano T; Yanoma S; Nakamura Y; Ozeki A; Kokatsu T; Kubota A; Furukawa M; Tsukuda M Acta Otolaryngol; 2005 Apr; 125(4):392-7. PubMed ID: 15823810 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer. Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528 [TBL] [Abstract][Full Text] [Related]
8. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer. Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697 [TBL] [Abstract][Full Text] [Related]
9. Preferential overexpression of CD44v5 in advanced gastric carcinoma Goseki grades I and III. Stachura J; Krzeszowiak A; Popiela T; Urbańczyk K; Pituch-Noworolska A; Wieckiewicz J; Zembala M Pol J Pathol; 1999; 50(3):155-61. PubMed ID: 10624117 [TBL] [Abstract][Full Text] [Related]
10. Serum levels of transforming growth factor alpha in gastrointestinal cancer patients. Moskal TL; Huang S; Ellis LM; Fritsche HA; Chakrabarty S Cancer Epidemiol Biomarkers Prev; 1995 Mar; 4(2):127-31. PubMed ID: 7742720 [TBL] [Abstract][Full Text] [Related]
11. Soluble CD44 and CD44v6 serum levels in patients with colorectal cancer are independent of tumor stage and tissue expression of CD44v6. Weg-Remers S; Hildebrandt U; Feifel G; Moser C; Zeitz M; Stallmach A Am J Gastroenterol; 1998 May; 93(5):790-4. PubMed ID: 9625129 [TBL] [Abstract][Full Text] [Related]
12. [Plasma neuropeptide Y (NPY) levels in patients with gastric and colorectal carcinomas]. Li Y; Chen S; Li Z Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):213-5. PubMed ID: 10921011 [TBL] [Abstract][Full Text] [Related]
13. Preoperative serum angiopoietin-2 levels correlate with lymph node status in patients with early gastric cancer. Jo MJ; Lee JH; Nam BH; Kook MC; Ryu KW; Choi IJ; Kim YW; Bae JM Ann Surg Oncol; 2009 Jul; 16(7):2052-7. PubMed ID: 19408052 [TBL] [Abstract][Full Text] [Related]
14. [Univariate and multivariate regression analyses of recurrence and metastasis of colon cancer after radical resection]. Ren JQ; Zhou ZW; Wan DS; Lu ZH; Chen G; Wang GQ; Tang SX; Wang JJ Ai Zheng; 2006 May; 25(5):591-5. PubMed ID: 16687080 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of soluble CD44v6 as a potential serum marker for head and neck squamous cell carcinoma. Van Hal NL; Van Dongen GA; Ten Brink CB; Heider KH; Rech-Weichselbraun I; Snow GB; Brakenhoff RH Clin Cancer Res; 1999 Nov; 5(11):3534-41. PubMed ID: 10589769 [TBL] [Abstract][Full Text] [Related]
17. The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers. Coban S; Yüksel O; Koçkar MC; Köklü S; Basar O; Tutkak H; Ormeci N Hepatogastroenterology; 2007; 54(77):1472-6. PubMed ID: 17708279 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of CD44 variant 6 expression and clinicopathological factors in pulmonary metastases from colon carcinoma. Indinnimeo M; Cicchini C; Giarnieri E; Stazi A; Mingazzini PL; Stipa V Oncol Rep; 2003; 10(6):1875-7. PubMed ID: 14534711 [TBL] [Abstract][Full Text] [Related]
19. Profile of monocyte chemoattractant protein-1 circulating levels in gastric cancer patients. Tonouchi H; Miki C; Tanaka K; Kusunoki M Scand J Gastroenterol; 2002 Jul; 37(7):830-3. PubMed ID: 12190098 [TBL] [Abstract][Full Text] [Related]
20. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker. Wang CS; Wu TL; Tsao KC; Sun CF Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]